{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:41:25Z","timestamp":1768567285591,"version":"3.49.0"},"posted":{"date-parts":[[2024,7,27]]},"group-title":"Neurology","reference-count":20,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,7,27]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Biomarkers have been essential to understanding Alzheimer\u2019s disease (AD) pathogenesis, pathophysiology, progression, and treatment effects. However, each biomarker measure is a representation of the biological target, the assay used to measure it, and the variance of the assay. Thus, biomarker measures are difficult to compare without standardization, and the units and magnitude of effect relative to the disease are difficult to appreciate, even for experts. To facilitate quantitative comparisons of AD biomarkers in the context of biologic and treatment effects, we propose a biomarker standardization approach between normal ranges and maximum abnormal AD ranges, which we refer to as CentiMarker, similar to the Centiloid approach used in PET.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We developed a standardization scale that creates percentile values ranging from 0 for a normal population to 100 for the most abnormal measures across disease stages. We applied this scale to CSF and plasma biomarkers in autosomal dominant AD, assessing the distribution by estimated years from symptom onset, between biomarkers, and across cohorts. We then validated this approach in a large national sporadic AD cohort.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found the CentiMarker scale provided an easily interpretable metric of disease abnormality. The biologic changes, range, and distribution of several AD fluid biomarkers including amyloid-\u03b2, phospho-tau and other biomarkers, were comparable across disease stages in both early onset autosomal dominant and sporadic late onset AD.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The CentiMarker scale offers a robust and versatile framework for the standardized biological comparison of AD biomarkers. Its broader adoption could facilitate biomarker reporting, allowing for more informed cross-study comparisons and contributing to accelerated therapeutic development.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.07.25.24311002","type":"posted-content","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T15:00:12Z","timestamp":1722092412000},"source":"Crossref","is-referenced-by-count":3,"title":["The CentiMarker Project: Standardizing Quantitative Alzheimer\u2019s disease Fluid Biomarkers for Biologic Interpretation"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-8737","authenticated-orcid":false,"given":"Guoqiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"McDade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-1699","authenticated-orcid":false,"given":"Jeffrey L.","family":"Dage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-622X","authenticated-orcid":false,"suffix":"Jr","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2381-7059","authenticated-orcid":false,"given":"Laura","family":"Ibanez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigyasha","family":"Timsina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-2899","authenticated-orcid":false,"given":"Cruchaga","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the DIAN-TU Study Team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":false,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024073007400578000_2024.07.25.24311002v1.1","unstructured":"Salloway S , Farlow M , McDade E , et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nature Medicine. 2021:1\u201310."},{"key":"2024073007400578000_2024.07.25.24311002v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJ-Moa2212948"},{"key":"2024073007400578000_2024.07.25.24311002v1.3","unstructured":"Sims JR , Zimmer JA , Evans CD , et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023."},{"issue":"1","key":"2024073007400578000_2024.07.25.24311002v1.4","first-page":"e12367","article-title":"Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Diagnosis","volume":"14","year":"2022","journal-title":"Assessment & Disease Monitoring"},{"key":"2024073007400578000_2024.07.25.24311002v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.05.014"},{"key":"2024073007400578000_2024.07.25.24311002v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2021-003310"},{"key":"2024073007400578000_2024.07.25.24311002v1.7","doi-asserted-by":"crossref","unstructured":"Timsina J , Ali M , Do A , et al. Harmonization of CSF and imaging biomarkers in Alzheimer\u2019s disease: Need and practical applications for genetics studies and preclinical classification. Neurobiology of Disease. 2024;190:106373.","DOI":"10.1016\/j.nbd.2023.106373"},{"key":"2024073007400578000_2024.07.25.24311002v1.8","doi-asserted-by":"crossref","unstructured":"Wang G , Li Y , Xiong C , et al. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2024.","DOI":"10.1002\/alz.13735"},{"issue":"12","key":"2024073007400578000_2024.07.25.24311002v1.9","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","year":"2022","journal-title":"JAMA neurology"},{"key":"2024073007400578000_2024.07.25.24311002v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"issue":"14","key":"2024073007400578000_2024.07.25.24311002v1.11","first-page":"e1295","article-title":"Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease","volume":"91","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"2024073007400578000_2024.07.25.24311002v1.12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jalz.2018.12.019","article-title":"Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer\u2019s disease","volume":"15","year":"2019","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"4","key":"2024073007400578000_2024.07.25.24311002v1.13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jalz.2018.12.008","article-title":"Staging biomarkers in preclinical autosomal dominant Alzheimer\u2019s disease by estimated years to symptom onset","volume":"15","year":"2019","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"10","key":"2024073007400578000_2024.07.25.24311002v1.14","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/alz.12505","article-title":"Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease","volume":"18","year":"2022","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"2024073007400578000_2024.07.25.24311002v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.07.003"},{"key":"2024073007400578000_2024.07.25.24311002v1.16","doi-asserted-by":"crossref","unstructured":"Wagemann O , Liu H , Wang G , et al. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA neurology. 2024.","DOI":"10.1001\/jamaneurol.2024.3828"},{"key":"2024073007400578000_2024.07.25.24311002v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0781-z"},{"key":"2024073007400578000_2024.07.25.24311002v1.18","doi-asserted-by":"crossref","unstructured":"Li Y , Yen D , Hendrix RD , et al. Timing of Biomarker Changes in Sporadic Alzheimer\u2019s Disease in Estimated Years from Symptom Onset. Annals of Neurology. 2024.","DOI":"10.1002\/ana.26891"},{"issue":"3","key":"2024073007400578000_2024.07.25.24311002v1.19","first-page":"e12465","article-title":"Harmonization and standardization of biofluid-based biomarker measurements for AT (N) classification in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Diagnosis","volume":"15","year":"2023","journal-title":"Assessment & Disease Monitoring"},{"issue":"2","key":"2024073007400578000_2024.07.25.24311002v1.20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/09622802231215810","article-title":"Correlational analyses of biomarkers that are harmonized through a bridging study due to measurement errors","volume":"33","year":"2024","journal-title":"Statistical methods in medical research"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.07.25.24311002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:07:53Z","timestamp":1768507673000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.07.25.24311002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1101\/2024.07.25.24311002","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1002\/alz.14587","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,7,27]]},"subtype":"preprint"}}